Drugs / 177Lu-DTPA-omburtamab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07698899 | Jul 2026 → Jun 2030 expected | medulloblastoma, metastatic malignant neoplasm in the brain | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04315246 | Aug 2022 → Dec 2024 | neoplastic meningitis | Y-mAbs Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04167618 | Sep 2021 → Aug 2022 | childhood medulloblastoma | Y-mAbs Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DTPA-omburtamab | “Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.” NCT04315246 ↗2“A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)” NCT07698899 ↗ |
| Known as | Drug: 177Lu-DTPA-omburtamab | “Drug: 177Lu-DTPA-omburtamab” NCT04315246 ↗ |
| Modality | Monoclonal antibody | “which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3” NCT04167618 ↗ |
| Route | Other | “Intracerebroventricular administration of 177Lu-DTPA-omburtamab” NCT04167618 ↗ |